Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
NCT01649050 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2017-04-20
Summary
To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis
Conditions
- Muscle Spasticity Due to Multiple Sclerosis
Interventions
- DRUG
-
BGG492
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-10-31
- Primary Completion
- 2018-03-31
- Completion
- 2018-03-31
More Related Trials
-
Cause, Development, and Progression of Stiff-Person Syndrome
NCT00030940 ·Status: COMPLETED
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Rituximab to Treat Neuropathy With Anti-MAG Antibodies
NCT00050245 ·Status: COMPLETED ·Phase: PHASE2
-
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
NCT04054414 ·Status: RECRUITING ·Phase: PHASE2
-
Stellate Ganglion Block in Longstanding Facial Nerve Palsy Patients
NCT06742255 ·Status: NOT_YET_RECRUITING
-
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
NCT06447597 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
NCT05974293 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
NCT01423110 ·Status: COMPLETED ·Phase: PHASE2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
NCT02110706 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
NCT06436742 ·Status: RECRUITING ·Phase: PHASE1
-
Mycophenolate Mofetil in Myasthenia Gravis
NCT00285350 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
NCT02473965 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954 ·Status: RECRUITING ·Phase: PHASE2
-
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
NCT02565576 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
NCT03896295 ·Status: TERMINATED ·Phase: PHASE2
-
Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
NCT00306033 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.
NCT01827072 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348 ·Status: RECRUITING ·Phase: PHASE2
-
Efgartigimod for Consolidation Therapy in gMG
NCT07079020 ·Status: NOT_YET_RECRUITING
-
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
NCT07287982 ·Status: RECRUITING ·Phase: PHASE2
-
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
NCT01268280 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
NCT00727194 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
NCT00515450 ·Status: COMPLETED ·Phase: PHASE3
-
Disease-Modifying Treatments for Myasthenia Gravis
NCT03490539 ·Status: COMPLETED